An immunological mechanism of resistance to CDK4/6 inhibitors in HR+ breast cancer

CDK4/6 inhibitors are central to the clinical management of HR+HER2− breast cancer. We have recently demonstrated that immunosuppressive, IL17-secreting γδ T cells recruited to the tumor microenvironment by a CCL2-dependent mechanism upon CDK4/6 inhibition can repolarize tumor-associated macrophages...

Full description

Bibliographic Details

Published in:	OncoImmunology
Main Authors:	Claudia Galassi, Giulia Petroni, Simon R.V. Knott, Lorenzo Galluzzi
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2025-12-01
Subjects:	Circulating biomarker endocrine therapy hypoxia palbociclib single-cell RNA sequencing TAMs
Online Access:	https://www.tandfonline.com/doi/10.1080/2162402X.2025.2520269